

# pFUSEN-hG1e2Fc

Plasmid designed for the fusion of an Fc domain to the N-terminus of a protein of interest

Catalog # pfcn-hg1e2

For research use only

Version # 13H28-JC-35

## PRODUCT INFORMATION

### Content:

- 20  $\mu$ g of pFUSEN-hG1e2Fc plasmid provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

### Storage and Stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C and is stable 3 months.
- Resuspended DNA should be stored at -20°C and is stable up to 1 year.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

### Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

## GENERAL PRODUCT USE

pFUSEN-Fc is a family of plasmids developed to facilitate the construction of Fc-fusion proteins where the immunoglobulin G (IgG) Fc-domain is fused to the N-terminus of the protein of interest.

pFUSEN-Fc plasmids yield high levels of Fc-fusion proteins. The level of expression is usually in the  $\mu$ g/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, CHO cells, monkey COS cells and human embryonic kidney (HEK) 293 cells, cells that are commonly used in protein purification systems.

A choice of cloning sites is provided to allow flexibility in the design of the fusion linker: either use pFUSEN linker, or bring forth your own linker with the protein of interest.

pFUSEN-Fc plasmids allow the secretion of Fc-Fusion proteins. They contain the human IL2 signal sequence (IL2ss). As Fc-Fusion proteins are secreted, they can be easily detected in the supernatant of pFUSEN-Fc-transfected cells by SDS-PAGE. Furthermore, functional domains can be identified by immunoblotting and ligand blotting.

Fc-Fusion proteins can be easily purified by protein A or protein G affinity chromatography.

InvivoGen provides pFUSEN-Fc vectors featuring Fc regions from different species and isotypes. In humans, three options are available: IgG1, IgG1e2, or IgG2. The Fc region mediates effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). IgG isoforms exert different levels of effector functions. The engineered IgG1e2 contains mutations in the FcRn binding sites leading to higher FcRn binding affinity and reduced pH dependence.

## PLASMID FEATURES

• **Human IgG1e2-Fc:** The Fc region comprises the CH2 and CH3 domains of the IgG1 heavy chain, with the hinge region. The first cysteine of the hinge has been replaced by a serine to prevent detrimental disulfite bridges. The last amino acid (lysine) of the Fc region has been replaced by an alanine for better fusion result.

The Fc region binds to neonatal FcR (FcRn), a receptor expressed on the surface of endothelial cells. This interaction, which is pH-dependent, protects the IgG from lysosomal degradation thus mediating the serum persistence of IgG antibodies. The human “IgG1e2” Fc domain was engineered to introduce mutations in the FcRn binding sites leading to higher FcRn binding affinity and reduced pH dependence<sup>5</sup>. hIgG1e2 Fc contains the following mutations: M252Y/S254T/T256E and H433K/N434F.

• **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1 $\alpha$  (EF-1 $\alpha$ ) core promoter<sup>1</sup> and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat<sup>2</sup>. The EF-1 $\alpha$  promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1 $\alpha$  core promoter to enhance stability of RNA.

• **IL2 ss:** The IL2 signal sequence contains 20 amino acids and share common characteristics with signal peptides of other secretory proteins. The intracellular cleavage of the IL2 signal peptide occurs after Ser20 and leads to the secretion of the fusion protein.

• **Cloning sites & fusion linker:** The protein of interest can be cloned either as a BamHI—NheI fragment, or as an EcoRV—NheI fragment, or as a BsiWI—NheI fragment. With BamHI or EcoRV cloning, the protein of interest will be separated from the Fc-domain by a flexible linker (Gly<sub>4</sub>Ser dimer). With BsiWI cloning, the flexible linker will not be retained, allowing for a different fusion design.

The provided cloning sites are compatible with many other enzymes, thus facilitating cloning.

• **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA<sup>3</sup>.

• **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **CMV enh / hFerL prom:** This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin™-resistance gene in mammalian cells.

• **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.

• **Zeo:** Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptoalloteichus hindustanus*. The same resistance gene confers

## TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: [info@invivogen.com](mailto:info@invivogen.com)

selection in both mammalian cells and *E. coli*.

• **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription<sup>4</sup>.

1. Kim DW *et al.* 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23.
2. Takebe Y. *et al.* 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72.
3. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58.
4. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.
5. Vaccaro C. *et al.* 2005. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 23(10):1283-8.

## METHODS

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H<sub>2</sub>O. Store resuspended plasmid at -20 °C.

### Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

### Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.


## RELATED PRODUCTS

| Product | Catalog Code |
|---------|--------------|
| Zeocin™ | ant-zn-1     |

---

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873  
InvivoGen USA (International): +1 (858) 457-5873  
InvivoGen Europe: +33 (0) 5-62-71-69-39  
InvivoGen Hong Kong: +852 3622-3480  
E-mail: [info@invivogen.com](mailto:info@invivogen.com)



**PvuI (7)**  
**SgfI (6)**  
 1 GGATCTGGATCGCTCCGGTGCCCGTCAGTGGGAGAGCGCACATCGCCACAGTCCCGGAGAAGTTGGGGGAGGGGTGGCAATTGAACGGGTGCCTA  
 101 GAGAAGGTGGCGCGGGTAAACTGGAAAGTGATGTCGTGTAAGTGGCTCCGCCTTTTCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGCC

---

**HindIII (245)**  
**Psp1406I (203)** **PvuII (239)**  
 201 GTGAACGTTCTTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCTTACCGCGCCGCCCTACCTGAGGCC  
 301 GCCATCCACGCGGTTGAGTTCGCGTTTCTGCCGCTCCCGCCTGTGGTGCCTCTGAACTGCGTCCGCGCTAGGTAAGTTTAAAGCTCAGGTCGAGACC  
 401 GGGCCTTTGTCCGGGCTCCCTTGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCTGACCCTGCTTCTCAACTCTACGTTCTTTGTTTCGTTT

---

**KasI (535)** **SgrAI (551)** **BsrGI (573)**  
 501 TCTGTTCTGCGCGTTACAGATCCAAGCTGTGACCGGGCGCTACCTGAGATCACCGGCGAAGGAGGGCCACCATGTACAGGATGCAACTCCTGTCTTGCA  
 1► M Y R M Q L L S C  
**EcoRI (625)** **XhoI (638)** **hinge Cys changed to Ser (653)**  
 601 TTGCACTAAGTCTTGCACTTGTACGAATTCGGCACCTCTCGAGCCAAATCTAGTGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAACTCCT  
 10► I A L S L A L V T N S A P L E P K S S D K T H T C P P C P A P E L L  
 701 GGGGGACCGTCACTTCTCTTCCCCAAAACCAAGGACACCCTCTACATCACCCGGGAACCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCA  
 23► G G P S V F L F P P K P K D T L Y I T R E P E V T C V V V D V S H  
**SacII (866)**  
 800 CGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGT  
 56► E D P E V K F N W Y V D G V E V H N A K T K P R E E Q Y N S T Y R  
 900 GTGGTCAGGTCCTCACCCTGACCCAGGACTGGCTGAATGGCAAGGAGTACAAGTCAAGTCTCCAACAAGCCCTCCAGCCCCATCGAGAAA  
 90► V V S V L T V L H Q D W L N G K E Y K C K V S N K A L P A P I E K

---

**BsrGI (1038)** **XmaI (1056)**  
 1000 CCATCTCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCTGCCCCATCCCGGGAGGAGTGAACCAAGAACCAGGTGACGCTGACCTGCCT  
 123► T I S K A K G Q P R E P Q V Y T L P P S R E E M T K N Q V S L T C L  
 1100 GGTCAAAGGCTTCTATCCAGCGACATGCCGTGGAGTGGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCTCCCGTCTGGACTCCGAC  
 156► V K G F T Y P S D I A V E W E S N G Q P E N N Y K T T P P V L D S D  
**XmnI (1255)** **NsiI (1277)**  
 1200 GGCTCCTTCTTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGAAGTTC  
 190► G S F F L Y S K L T V D K S R W Q Q G N V F S C S V M H E A L K F  
**NheI (1383)**  
**BsiWI (1337)** **EcoRV (1373)**  
**SapI (1309)** **Lys changed to Ala (1334)** **BamHI (1367)** **XhoI (1378)** **MseI (1389)**  
 1299 CACTACCGCAGAAGAGCCTCTCCCTGTCTCCGGGTGCACTACGGGTGGTGGCGGTAGCGGTGGTGGCGGATCCGATATCTCGAGCTAGCTGGCCAGAC  
 223► H Y T Q K S L S L S P G A  
 1► R T G G G G S G G G S D I S S •

---

**HpaI (1521)**  
 1499 CCATTATAAGCTGCAATAAACAAGTAAACAACAATTCATTTCATTTTATGTTTCAGGTTTCAGGGGAGGTGTGGGAGTTTTTAAAGCAAGTAAAA

---

**AseI (1619)** **XmnI (1617)**  
 1599 CCTCTACAAATGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAAT  
 1699 AAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAAGATATAGTGTATTTTCCCAAGGTTTG

---

**SapI (1803)** **SspI (1860)** **SwaI (1874)**  
 1799 AACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCACATTCCTTTTTAGTAAAAATATTGAGAAAATATTAAATACATCATTGCAATGAA  
 1899 AATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTCATAATATCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAG

---

**DraIII (2053)** **EagI (2073)**  
 1999 AAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCTGCTCCTCTGCCACAAAGTGCACGAGTTGCCGGCCGGGTCGCGCAGGGCGAACTC  
 1254► D Q E E A V F H V C N G A P D R L A F E  
 2099 CCGCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCGGAGGGCTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCC  
 104► R G W P Q E G I E T M A P G S A D R F N T S V V E S W E A Y L E D  
**SgrAI (2289)**  
 2199 AGGCCGCGCACCCACACCAGGCCAGGGTGTGTCCGGCACCCTGGTCTGGACCGCGCTGATGAACAGGGTACGTCGTCGCCGACCAACCGGGCGA  
 704► L G R V W V W A L T N D P V V Q D Q V A S I F L T V D D R V V G A F

---

**XmaI (2316)** **BsrBI (2352)** **BssHII (2368)**  
 2299 AGTCGTCCTCCAGGAAGTCCCGGAGAACCAGCCGGTCCGAGTCCAGAACTGACCCGCTCCGGCGACGTCGCGCGGGTGGACCCGGAACGGCACTGGT  
 374► D D E V F D R S F G L R D T W F E V A G A V D R A T L V P V A S T

---

**MseI (2403)**  
 2399 CAACTTGGCCATGATGGCTCCTCctgtcaggagaggaagagaagaggttagtacaattgCTATAGTGAAGTGTATTATACTATGCAGATATACTATGC  
 4► L K A M

---

**AseI (2503)** **PstI (2522)**  
 2499 CAATGATTAATTGTCAAACCTAGGGCTGCAGggttcatagtgccacttttctgcactgccccatctcctgcccaccctttccaggcatagacagtcagt

2599 *gacttac*CAAACCTCACAGGAGGGAGAAGGCAGAGCTTGAGACAGACCCGCGGGACCCGCAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGG  
HindIII (2630) SacII (2645)  
←

2699 TGC GCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCTAGCGGCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCAC  
StuI (2730) BspEI (2788)

2799 ATAGGAGTCTCAGCCCCCGCCCAAAGCAAGGGGAAGTCACGCGCTGTAGCGCCAGCGTGTGTGAAATGGGGGCTTGGGGGGTTGGGGCCCTGACT  
Bsp120I (2887) SpeI (2895)

2899 AGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGAAATCCCCGTGAGTCAAACCGCTATCCACGCCATTGATGTACTGCCAAAACCGCA  
←

2999 TCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACC  
SnaBI (3023)

3099 GTCATTGACGTCAATAGGGGGCGTACTTGCCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGG  
NdeI (3128)

3199 AAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGTCGTTGGGCGGTGAGCCAGGCGGGCCATTTACCGTAAGTT

3299 ATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCCGCTTGTGGCGTTTTTCCATAGGCTC  
PstI (3307) PacI (3314) SdaI (3306) BspLU11I (3324)  
←

3399 CGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGCGTTTTCCCTGGAAGCTCCC

3499 TCGTGGCTCTCCTGTTCCGACCTGCCGTTACCGGATACCTGTCCGCCTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCACGCTGTAGGTA

3599 TCTCAGTTCGGTGTAGGTCGTTGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAG

3699 TCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT

3799 GGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGAAAAAGAGTTGGTAGCTCTTGATCCGG

3899 CAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGGTTTGAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTCTACG

3999 GGGTCTGACGCTCAGTGGAACGAAAACCTACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATT  
PacI (4054) SwaI (4063) EagI (4074) NotI (4073)

4099 TTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAACAAAACGAAACAAAACAACTAGCAAATAGGCTGTC

4199 CCCAGTGAAGTGCAAGTGCCAGAACATTTCTCTATCGAA